Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBIT Margin (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EBIT Margin for 14 consecutive years, with 26.18% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 356.0% year-over-year to 26.18%, compared with a TTM value of 21.64% through Dec 2025, down 258.0%, and an annual FY2025 reading of 21.64%, down 258.0% over the prior year.
  • EBIT Margin was 26.18% for Q4 2025 at Neurocrine Biosciences, down from 30.07% in the prior quarter.
  • Across five years, EBIT Margin topped out at 418.67% in Q2 2021 and bottomed at 27.16% in Q1 2023.
  • Average EBIT Margin over 4 years is 44.75%, with a median of 22.62% recorded in 2024.
  • The sharpest move saw EBIT Margin soared 39334bps in 2021, then crashed -1515bps in 2025.
  • Year by year, EBIT Margin stood at 15.03% in 2021, then surged by 94bps to 29.17% in 2023, then dropped by -22bps to 22.62% in 2024, then increased by 16bps to 26.18% in 2025.
  • Business Quant data shows EBIT Margin for NBIX at 26.18% in Q4 2025, 30.07% in Q3 2025, and 21.18% in Q2 2025.